La vendita allo scoperto per P3 Health Partners dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di P3 Health Partners. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

P3 Health Partners (NASDAQ:PIII) Azioni, Report sulle vendite allo scoperto

P3 Health Partners

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

Long Ideas

News

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

BCOV

PIII

PODC

Scopri le penny stock sotto i $3 che gli insider stanno acquistando, tra cui PodcastOne e altre opportunità nascoste.

Le migliori penny stock sotto $3 che gli insider stanno acquistando

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners Inc

U.S. stocks traded mixed this morning, with the Dow Jones falling over 100 points on Friday.
Following the market opening Friday, the Dow traded down 0.35% to 43,086.52 while the NASDAQ rose 0.73% to 18,507.31. The S&amp;P 500 also rose, gaining, 0.26% to 5,856.65.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a>
Leading and Lagging Sectors Communication services shares jumped by 1.4% on Friday.
In trading on Friday, energy shares fell by 0.6%.
Top Headline
Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported stronger-than-expected third-quarter financial results, posting revenue of $9.825 billion, up 15% year-over-year, versus market estimates of $9.769 billion.
The company ended the third quarter with 282.72 million global paid subscribers, up 14.4% year-over-year.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Catheter Precision, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NASDAQ">VTAK</a>) shares shot up 249% to $1.54.</li>
<li>Shares of Bright Minds Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) got a boost, surging 133% to $50.66. The company announced a $35 million non-brokered private placement.</li>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares were also up, gaining 96% to $15.55 after the company announced it filed a form RW and will not pursue a public offering at this time.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares dropped 38% to $0.4301.</li>
<li>Shares of Orgenesis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) were down 34% to $2.1100.</li>
<li>NuZee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUZE#NASDAQ">NUZE</a>) was down, falling 31% to $1.5950.</li>
</ul>
Commodities In commodity news, oil traded down 1.5% to $69.59 while gold traded up 0.8% at $2,730.00.
Silver traded up 2.9% to $32.690 on Friday, while copper rose 1.3% to $4.3815.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.1%, Germany's DAX rose 0.2% and France's CAC 40 climbed 0.2%. Spain's IBEX 35 Index fell 0.2%, while London's FTSE 100 fell 0.8%.
Construction output in the Eurozone fell by 2.5% year-over-year in August compared to a revised 2.3% decline in the previous month. The current account surplus in the Eurozone increased to €35.2 billion in August from €26.8 billion in the year-ago period.
Asia Pacific Markets
Asian markets closed higher on Friday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index climbing 3.61%, China's Shanghai Composite Index gaining 2.91% and India's BSE Sensex gaining 0.27%.
Economics
<ul>
<li>U.S. housing starts fell by 0.5% from the previous month to an annualized rate of 1.354 million units in September.</li>
<li>Building permits declined by 2.9% to an annual rate of 1.428 million in September.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41402086/wall-streets-most-accurate-analysts-give-their-take-on-3-financials-stocks-delivering-hi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financials Stocks Delivering High-Dividend Yields</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

DRUG

NFLX

NKGN

NUZE

ORGS

SOBR

VTAK

Dow Falls Over 100 Points; Netflix Posts Upbeat Results

Piper Sandler analyst Stephen Scouten maintains Bank OZK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZK#NASDAQ">OZK</a>) with a Overweight and raises the price target from $58 to $63.

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on Bank OZK, Raises Price Target to $63

Canaccord Genuity analyst Brian McNamara maintains Hillman Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) with a Buy and maintains $13 price target.

HLMN

Canaccord Genuity Maintains Buy on Hillman Solns, Maintains $13 Price Target

Argus Research downgrades Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) from Buy to Hold.

Downgrades

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Argus Research Downgrades Elevance Health to Hold

Canaccord Genuity analyst Maria Ripps maintains Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) with a Hold and raises the price target from $11 to $13.

Canaccord Genuity Maintains Hold on Viant Technology, Raises Price Target to $13

Autoliv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) shares are <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41398774/autoliv-financial-report-july-september-2024" rel="noreferrer noopener">trading higher on Friday.</a>
The company reported third-quarter adjusted earnings per share of $1.84, missing the analyst consensus of $1.95. Quarterly revenues of $2.56 billion topped the street view of $2.53 billion.
In the third quarter, sales fell by 0.8% organically. The firm performed well in Europe and Asia (excluding China) due to numerous product launches and favorable pricing.
Sales to domestic Chinese OEMs increased by 18%, outpacing their LVP growth of 8.5%. 
However, the firm struggled in China because of a negative mix, with sales of lower-safety models rising while higher-end models declined.
The company&#8217;s adjusted operating margin decreased to 9.3% from 9.4%.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/10/41399541/apple-iphone-16-sees-20-sales-surge-in-china-but-ai-absence-prompts-early-price-cuts" rel="noreferrer noopener">Apple iPhone 16 Sees 20% Sales Surge in China, But AI Absence Prompts Early Price Cuts</a>
&#8220;Light vehicle production was weak in the third quarter, declining by close to 5% globally. This was driven by a combination of inventory reductions, especially in the Americas and a high comparison base, especially in&nbsp;China,&#8221; said Mikael Bratt, President &amp; CEO.
The CEO indicated that, given recent sales trends and order intake, the company anticipates gaining more market share with domestic Chinese OEMs in the coming years.
Bratt also noted that negotiations for excess inflation compensation with customers have progressed as expected, although a few are still pending.
Outlook: Autoliv now expects full-year 2024 organic sales growth to be 1%, down from the previously anticipated 2%, <a href="https://www.benzinga.com/calendars/guidance">due to unfavorable market mix developments.</a>
With the seasonally strong fourth quarter remaining of the year, the company reaffirmed its guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.
Price Action: ALV shares are trading higher by 5.69% to $99.24 at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41388050/apples-3nm-push-boosts-taiwan-semis-q3-ai-revenue-set-to-triple-analyst" target="_blank" rel="noreferrer noopener">Apple&#8217;s 3nm Push Boosts Taiwan Semi&#8217;s Q3, AI Revenue Set To Triple: Analyst</a></li>
</ul>

Earnings

Guidance

Movers

General

Autoliv Surges Despite Mixed Q3 Results: Chinese Market Mix Drags  Performance

Piper Sandler analyst Adam Maeder reiterates Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Overweight and raises the price target from $495 to $538.

Reiteration

ISRG

Piper Sandler Reiterates Overweight on Intuitive Surgical, Raises Price Target to $538

Canaccord Genuity analyst Kingsley Crane maintains BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) with a Hold and raises the price target from $2.7 to $2.8.

Canaccord Genuity Maintains Hold on BlackBerry, Raises Price Target to $2.8

LYFT

Lyft Option Alert: 1,000 Contracts Of Oct 25 $14 Calls Swept Near The Ask At $0.26; Open Interest 2,062; Stock At $13.75 Ahead Of 11/6 Earnings

Piper Sandler analyst Matt O'Brien reiterates Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $200 to $225.

Piper Sandler Reiterates Overweight on Penumbra, Raises Price Target to $225

Alliance Global Partners initiates coverage on Global Self Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SELF#NASDAQ">SELF</a>) with a Buy rating and announces Price Target of $6.5.

Initiation

SELF

Alliance Global Partners Initiates Coverage On Global Self Storage with Buy Rating, Announces Price Target of $6.5

At the <a href="https://www.benzinga.com/events/">Benzinga Cannabis Capital Conference</a>, actor and cannabis advocate Jim Belushi emphasized the urgent need for cannabis policy reform, particularly around banking and taxation. As the founder of Belushi's Farm, he's not only invested in the cultivation of cannabis, but also in changing the way the plant is regulated and perceived in both the medical and recreational spaces.
Belushi pointed out the stark contrast between how cannabis and alcohol are treated in terms of taxation, using Illinois as an example. "Last year, they collected $474 million in cannabis taxes and $272 million in liquor taxes. And there are a lot more liquor stores and bars than dispensaries," Belushi said, highlighting the disproportionate burden placed on the cannabis industry.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Benzinga&#39;s Abbey Higginbotham chatted with <a href="https://twitter.com/JimBelushi?ref_src=twsrc%5Etfw">@JimBelushi</a> – Founder, Belushi&#39;s Farm <a href="https://t.co/sdlOi13UvO">pic.twitter.com/sdlOi13UvO</a>
&mdash; Benzinga (@Benzinga) <a href="https://twitter.com/Benzinga/status/1844800130496553364?ref_src=twsrc%5Etfw">October 11, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h3 class="wp-block-heading">Advocating For Change</h3>
Belushi has been a vocal proponent of cannabis reform, particularly the need to remove the plant from its classification as a Schedule I drug and to pass the Safe Banking Act, which would allow cannabis businesses more accessible access to financial services. "Let's get it off Schedule I. Let's pass the Banking Act. Let's bring down some regulations and over-taxation," he said.
He further stressed that cannabis offers a safer alternative to alcohol, saying, "Cannabis doesn't kill anybody. Alcohol does. It kills lots of people." This comparison underlines his argument for leveling the playing field between the two substances.
<h3 class="wp-block-heading">The Broader Impact of Cannabis Advocacy</h3>
Belushi also spoke about his broader advocacy for cannabis as a tool for healing, particularly in light of personal tragedies such as the loss of his brother John to an overdose. "Cannabis is a gentler alternative than opioids or overuse of alcohol to suppress anxiety and trauma," he said.
Through his platform and his involvement in the cannabis industry, Belushi is pushing for policy changes that not only benefit businesses but also help individuals find alternatives to harmful substances. As he noted, "People are suffering out there, and I think cannabis is the gentle way to help."
Belushi's continued efforts in the public and political arenas demonstrate his commitment to cannabis as more than just a business—it's a movement for broader social change.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Don't miss your chance to be part of Cannabis Market Spotlight: California in Anaheim on Nov. 12. Whether you want to connect with industry leaders, explore investment opportunities, or gain the latest insights into California's cannabis market, this event has it all.&nbsp;<a href="https://cannabismarketspotlight.com/california/anaheim-november-12/" target="_blank" rel="noreferrer noopener">Secure your spot today!</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free.&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe?_gl=1&#x2A;1ajl6va&#x2A;_gcl_au&#x2A;NjI5OTQ1MTM5LjE3Mjc5MzA5MjI.&#x2A;_ga&#x2A;MTAyOTE3MTY5OC4xNzI3OTMwOTIy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcyODkxMjAzOS41LjEuMTcyODkxMjEyMC4wLjAuMA.." target="_blank" rel="noreferrer noopener">Subscribe</a>&nbsp;to our newsletter here. You can't afford to miss out if you're serious about the business.
Jim Belushi speaks at the Benzinga Cannabis Capital Conference. Photo by Wendy Davis.

Cannabis

Politics

Events

Exclusives

Interview

EXCLUSIVE: Jim Belushi Speaks Out On Marijuana Reform, Says 'Cannabis Doesn't Kill Anybody, Alcohol Does'

UBS analyst Lloyd Byrne maintains Suncor Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SU#TSX">SU</a>) with a Buy and lowers the price target from C$63 to C$61.

TSX:SU

UBS Maintains Buy on Suncor Energy, Lowers Price Target to C$61

Piper Sandler analyst Matt Farrell reiterates Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Overweight and raises the price target from $800 to $840.

Piper Sandler Reiterates Overweight on Netflix, Raises Price Target to $840

RBC Capital analyst Jon Arfstrom maintains Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) with a Sector Perform and raises the price target from $73 to $83.

TCBI

RBC Capital Maintains Sector Perform on Texas Capital Bancshares, Raises Price Target to $83

<a href="https://www.benzinga.com/personal-finance/24/10/41335504/billionaire-mark-cuban-warns-when-you-win-the-lottery-never-invest-stick-it-in-the-bank-and-live">Mark Cuban may be worth billions</a> today, but it wasn't always that way. Cuban was once so broke he couldn't even scrape together the $200 needed to open a bank account. This personal anecdote was shared during the latest episode of Shark Tank, where Cuban reflected on his early days while hearing a pitch from Spare, a virtual ATM network aimed at the underbanked.
"When I was broke and sleeping on the couch, I couldn't open a bank account. You needed $200," Cuban explained, before committing $500,000 to the startup.
Don't Miss:
<ul>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a></li>
</ul>
Cuban's journey from couch-surfing to billionaire status is well-known, but the details offer insight into the <a href="https://www.benzinga.com/startups/24/10/41359639/it-was-amazing-says-mark-cuban-of-his-80s-ponzi-scheme-that-got-him-through-college-made-sure-his-fr">grit that powered his rise</a>. Born in Pittsburgh, Cuban grew up in a working-class family. He started a business early as a teenager, reselling baseball cards, stamps and coins. But not everyone believed in his potential. "People thought I might go work at a mill," he said. "My mom even wanted me to learn how to lay carpet."
See Also: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
After graduating from Indiana University, Cuban arrived in Dallas with just $60 in his pocket. He <a href="https://www.benzinga.com/personal-finance/24/08/40442345/mark-cuban-says-he-drove-cars-that-cost-200-with-holes-in-the-floorboard-and-lived-off-mac-and-c">shared a small apartment with five other guys</a>, sleeping on the floor or couch and worked as a bartender to make ends meet. Cuban's initial career stints didn't go smoothly either; he said he quit or was fired from three jobs in a row.
But then he found his footing in technology. "When I started working with computers, I realized I could go hours without even noticing time passing. That's when I knew I had found something I loved," he shared in a previous episode of Shark Tank. Cuban's tech passion eventually led him to launch MicroSolutions, which he sold for $6 million in 1990.
Trending: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
Cuban's next big break came in 1995 when he and Todd Wagner launched Broadcast.com, an online streaming service born out of their desire to listen to Indiana Hoosiers games from Texas. Yahoo bought the company in 1999 for $5.7 billion in stock.
"Nobody had high hopes for me," Cuban reflected. "But I was a hustler." His story, from struggling to open a bank account to becoming a billionaire, shows how far determination – and a little tech savvy – can go.
Trending: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
When you hear about a self-made billionaire, there's usually a moment when you're bracing for that "Surprise!" – the part where a rich relative swoops in with a hefty check. After all, real life doesn't usually involve fairy godmothers.&nbsp;
But in Cuban's tale, there's no twist, no secret benefactor. His story reads like a bona fide rags-to-riches saga, where every dollar was earned the hard way. No hidden chapters, no magical shortcuts – just a <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">relentless grind</a> that turned into a $5 billion net worth.
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>

Personal Finance

Mark Cuban Was So Broke He Didn't Even Have $200 Needed To Open A Bank Account And Now He's Worth Billions – 'Nobody Had High Hopes For Me'

MetroCity Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCBS#NASDAQ">MCBS</a>) reported quarterly earnings of $0.65 per share which met the analyst consensus estimate. The company reported quarterly sales of $36.904 million which beat the analyst consensus estimate of $36.200 million by 1.94 percent. This is a 36.40 percent increase over sales of $27.056 million the same period last year.

Earnings Beats

METROCITY BANKSHARES INC by MetroCity Bankshares Inc.

MCBS

MetroCity Bankshares Q3 2024 GAAP EPS $0.65, Inline, Sales $36.904M Beat $36.200M Estimate

Looking into the current session, Campbell Soup Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) shares are trading at $48.48, after a 0.47% drop. Over the past month, the stock decreased by 5.33%, but over the past year, it actually increased by 22.70%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1729260914_0.png" alt="Past Year Chart" />

<h3>A Look at Campbell Soup P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 33.69 in the Food Products industry, Campbell Soup Inc. has a lower P/E ratio of 25.77. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1729260914_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

P/E Ratio Insights for Campbell Soup

UBS analyst Joshua Chan maintains ManpowerGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) with a Neutral and lowers the price target from $78 to $71.

UBS Maintains Neutral on ManpowerGroup, Lowers Price Target to $71

Anthony Pompliano, CEO of Professional Capital Management, attributes the cryptocurrency market growth to <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41337016/anthony-pompliano-predicts-teslas-automation-tech-will-spike-stablecoin-adoption-people-do">broader global and sector-focused factors</a> but dismisses the notion that the U.S. presidential election plays a significant role.
What Happened: In an <a href="https://www.cnbc.com/video/2024/10/17/stablecoins-will-be-a-huge-bull-market-for-the-u-s-dollar-says-anthony-pompliano.html">appearance</a> on CNBC Squawk Box on Thursday, Pompliano linked this growth to the rising adoption of stablecoins.
Pompliano, who will be a headline speaker at Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19, noted that market conditions are favoring assets like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), which has seen a 60% rise this year. Contrary to popular belief, he doesn't associate Bitcoin&#8217;s surge with the election or any candidate.
Pompliano attributes Bitcoin&#8217;s rise to several factors: 
<ul>
<li>The post-halving supply shock</li>
<li>Lower interest rates from central banks</li>
<li>An expanding M2 money supply</li>
<li>Bullish investor sentiment</li>
</ul>
He predicts that Bitcoin's value will <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41044977/anthony-pompliano-says-bitcoin-set-to-be-a-big-winner-in-coming-months-due-to-cheap-money-">continue to climb</a> throughout the year and dismissed the concept of &#8220;Uptober,&#8221; noting that September was unexpectedly strong, countering traditional expectations of a market dip.
Pompliano described Bitcoin as "the simplest story in finance," though he acknowledges it&#8217;s challenging for traditional financial players to fully grasp.
He also highlighted the increasing use of stablecoins, predicting they will drive a significant bull market for the U.S. dollar. According to Pompliano, Bitcoin is being used as a digital savings account, while stablecoins serve as a checking account for everyday expenses, indicating a shift toward a multi-currency system.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41337016/anthony-pompliano-predicts-teslas-automation-tech-will-spike-stablecoin-adoption-people-do">Anthony Pompliano Predicts Tesla&#8217;s Automation Tech Will Spike Stablecoin Adoption: &#8216;People Don&#8217;t Want To Spend Their Bitcoin&#8217;</a>
Why It Matters: Pompliano emphasized that Bitcoin is not a threat to the U.S. dollar. Instead, he sees stablecoins as a major opportunity for the dollar in the digital currency space. This suggests that the rise of cryptocurrency ownership and stablecoin use could bolster the U.S. dollar's position in the global digital economy.
He also forecasted that Bitcoin&#8217;s momentum would continue through the year, with a possible correction followed by a shift to Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and other altcoins.
Pompliano also cited a recent report from Tether&#8217;s Head of Economics, revealing that over 330 million people are using Tether on-chain, with two-thirds of crypto users in emerging markets converting stablecoins into their local fiat currencies. Notably, 40% of these users have purchased goods or services with stablecoins.
What&#8217;s Next: Anthony Pompliano will be one of the headline speakers at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41292923/how-2024-presidential-election-could-impact-digital-assets-regulation-has-become-a-top-cam">How 2024 Presidential Election Could Impact Digital Assets: &#8216;Regulation Has Become A Top Campaign Issue,&#8217; Says Expert</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Bitcoin Is 'The Simplest Story In Finance,' Will Climb Regardless Of Election Winner, Says Anthony Pompliano

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
When does a growth stock become one of the top <a href="https://investorplace.com/stock-types/growth-stocks/">growth stocks</a> to avoid?



It sounds like the beginning of a riddle or a bad joke, but the answer is obvious &ndash; it&rsquo;s when the stock is deceptive and tricks you into believing that it can be a good buy. You look at the Portfolio Grader and get interested because a stock has a good grade specifically for growth, but then realize that it still has an &ldquo;F&rdquo; rating overall.



How can that happen?



The Portfolio Grader rates stocks based on earnings history, growth, analyst sentiment and momentum. The growth grade in particular is a popular metric for finding growth stocks to avoid.



But it&rsquo;s also important to see why a company is getting a good growth grade. Because sometimes, looking at a single factor like growth can be misleading and can&rsquo;t make up for the company&rsquo;s deficiencies in other areas.



Today, we&rsquo;re going to look at several companies that have good growth grades, and we&rsquo;ll investigate why that&rsquo;s happening in each case. But then we&rsquo;ll pull back the curtain, look at the fuller picture, and explore why these growth stocks to avoid are still getting &ldquo;F&rdquo; grades overall.



In the end, an exercise like this is a good reminder to not rely on any one metric when considering your stock portfolio. Growth is highly desirable, but the growth stocks to avoid on this list can easily drag your portfolio into the gutter.



<h2>Virgin Galactic (SPCE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/spce1600-300x169.jpg" alt="Virgin Galactic (SPCE) billboard on the New York Stock Exchange, across from the Fearless Girl statue. aerospace stocks"><div>Source: Tun Pichitanon / Shutterstock.com</div></div>It makes sense to jump right into one of the growth stocks to avoid that&rsquo;s been a huge disappointment &ndash; and has cost plenty of investors a lot of money along the way. 



Virgin Galactic (NYSE:<a href="https://investorplace.com/stock-quotes/spce-stock-quote/">SPCE</a>) made its name in the billionaire space race as founder Richard Branson competed with SpaceX and Blue Orgin to see which would be the first to make it into space with a civilian crew. 



You may remember that Virgin Galactic won that race, as it shot Branson into suborbital flight just a few days before Jeff Bezos did the same on a Blue Orgin rocket.



But honestly, that&rsquo;s the high point for this company. Space tourism doesn&rsquo;t feel any closer today than it did several years ago, and few people have the several hundred thousand dollars it takes to make the trip, even if the flights become a reality.



Virgin Galactic has burned through more than $1 billion in the last two years and rewarded investors with a 93% fall in stock price. SPCE recently completed a <a href="https://investorplace.com/2024/06/will-a-1-for-20-reverse-split-save-virgin-galactic-spce-stock/">1-for-20 reverse stock split</a> to push the price back over the Nasdaq threshold and maintain listing compliance, but the reality is that this is a bad stock and a weak company.



SPCE stock shows an &ldquo;A&rdquo; rating for growth in the Portfolio Grader because its revenue was up 410% in the last quarter. But sales of only $1.99 million show that people aren&rsquo;t lining up to ride a <a href="https://seekingalpha.com/article/4690417-virgin-galactic-holdings-inc-spce-q1-2024-earnings-call-transcript?source=content_type%3Areact%7Csection%3ATranscripts%7Csection_asset%3ATranscripts%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A2">Delta rocket</a> into space as early as 2026, which is the company&rsquo;s latest projections.



SPCE stock gets an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Helius Medical Technologies (HSDT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/tech1600a-300x169.jpg" alt="Image of hand touching globe with a city in the background, implying connectivity"><div>Source: Shutterstock</div></div>Helius Medical Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/hsdt-stock-quote/">HSDT</a>) is a neurotech company headquartered in eastern Pennsylvania. The company makes medical devices that help people with balance and gait issues without getting a neurological implant. It is also one of the growth stocks to avoid in the space.



The company&rsquo;s devices improve the brain&rsquo;s ability to compensate for deficiencies and rehabilitate lost brain function. For instance, its Portable Neuromodulation Stimulator stimulates the brain through nerves in the tongue. 



It&rsquo;s being used as a short-term treatment to help people with multiple sclerosis symptoms. But it&rsquo;s an expensive device, priced at more than $23,000.



The company saw <a href="https://ir.heliusmedical.com/news-releases/news-release-details/helius-medical-technologies-inc-reports-first-quarter-2024">revenue grow</a> in the first quarter, giving it a decent growth grade in the Portfolio Grader. But we&rsquo;re still not looking at a lot of money. Revenue in the first quarter was $135,000, versus $111,000 in the same quarter a year ago.



It posted a net loss of $2.5 million, the same as a year ago. The earnings per share loss of $3.08 was better than the loss of $4.22 per share from Q1 2023.



HSDT stock is down 87% this year. It has an &ldquo;A&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>InMed Pharmaceuticals (INM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/aurora-cannabis-stock-1-1-300x169.jpg" alt="cannabis stocks"><div>Source: Shutterstock</div></div>InMed Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/inm-stock-quote/">INM</a>) is a Canadian company that is a clinical-stage pharmaceutical company that&rsquo;s working to develop cannabis-infused treatments for Alzheimer&rsquo;s disease, vision and skin conditions.



The company is attempting to develop an effective pipeline of drug candidates targeting CB1 and CB2 receptors. 



Its attempt to develop an anti-itch skin cream is in Phase 2 testing, and it is seeking a partnership to help it develop the product. Its other pipeline candidates for Alzheimer&rsquo;s and dry age-related macular degeneration are in preclinical trials.



Developing new therapies is an expensive undertaking and a challenge for investors because the company has to spend a lot of cash on research and development without seeing income for years, if ever.



For the third fiscal quarter of 2024 (ending March 31), InMed reported a net loss of $5.7 million. The company saw sales of $1.1 million, up slightly from a year ago, and a gross profit of $289,000, which was better than its profit of $192,511 in the same quarter a year ago.



The profit increase helps InMed&rsquo;s growth grade in the Portfolio Grader. Still, the company also acknowledges that it has money only to finance research and development into the fourth calendar quarter of 2024. That is a worrisome disclosure.



INM stock gets a &ldquo;B&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader. The stock is down 36% this year.



<h2>P3 Health Partners (PIII)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/healthcare1600a-300x169.jpg" alt="stethoscope on a stock chart representing healthcare stocks to buy. Healthcare Stocks"><div>Source: Shutterstock</div></div>P3 Health Partners (NASDAQ:<a href="https://investorplace.com/stock-quotes/piii-stock-quote/">PIII</a>) is a health management company that supports providers with administrative services and coordination for their Medicare Advantage patients.



The company currently operates in Arizona, Oregon, Nevada, Florida and California, with a network of more than 2,900 primary care providers.



It recently announced raising <a href="https://ir.p3hp.org/news-events/press-releases/detail/106/p3-health-partners-inc-announces-approximately-42-2">$42.2 million</a> through the sale of 67.4 million units of stock with institutional investors, valued at just over 62 cents per share. That will give the company an infusion of cash to operate, but it also serves to dilute the share base.



First-quarter financial results included $388.5 million in revenue, up 29% from a year ago. But gross profits fell from $16.5 million to $6.4 million, and the company reported a net loss of $49.6 million.



PIII is among the growth stocks to avoid in part because it is down 62% this year. It gets an &ldquo;A&rdquo; rating for growth, but still has an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Sunshine Biopharma (SBFM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Sunshine Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbfm-stock-quote/">SBFM</a>) is a Florida-based biopharma company developing potential treatments in oncology and antivirals.



Thanks to its ownership of a Canadian pharmacy, Nora Pharma, which distributes generic medications, Sunshine was able to show <a href="https://sunshinebiopharma.com/wp-content/uploads/20240521_SBFM-Press-Release-Reports-Q1_2024_.pdf">sales</a> of $7.5 million in the first quarter, a gain from $4.8 million a year ago. That gives it a solid grade for growth in the Portfolio Grader.



However, Sunshine is a long path to ever bringing its own drugs to market, and that&rsquo;s where the real money is made. Sunshine is currently testing a Covid-19 treatment in mice at the University of Arizona in hopes of developing a treatment for patients who cannot use Paxlovid, Molnupiravir or Remdisivir.



It has a second drug candidate, to treat cancer, ready for testing on mice as well. However, the company&rsquo;s third drug candidate, also a cancer drug, is on hold after lab tests did not yield a favorable result.



The Nora Pharma sales weren&rsquo;t enough to help Sunshine generate a profit for the quarter, either. It posted a net loss of $1.2 million versus a loss of $1.7 million in the first quarter of 2023.



SBFM stock is down 98% this year. It gets an &ldquo;A&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>MicroVision (MVIS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/06/mvis1600-300x169.png" alt="Autonomous Self Driving Car Moving Through highway - Animated Scanning Visualization Concept of Artificial Intelligence Digitalizes and Analyzes Road Using Lidar. MVIS stock"><div>Source: aslysun / Shutterstock.com</div></div>With more vehicles on the road these days than ever, the advances in driver-assisted technology are pretty interesting. MicroVision (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvis-stock-quote/">MVIS</a>) makes automotive lidar sensors to help driver-assistance systems and autonomous vehicles function.



The company&rsquo;s sensors are also used in industrial, smart infrastructure and robotics.



It gets a good grade for growth in the Portfolio Grader because the company increased its revenue in the first quarter, bringing in $956,000 versus $782,000 in the first quarter of 2023. That&rsquo;s a healthy percentage increase that helps give it an &ldquo;A&rdquo; grade for growth.



But then look closer. MicroVision lost <a href="https://ir.microvision.com/news/press-releases/detail/402/microvision-announces-first-quarter-2024-results">$26.3 million in the quarter</a>, versus a loss of $19 million in the same quarter a year ago. When you&rsquo;re losing that much money, an $174,000 increase in revenue doesn&rsquo;t help that much.



MVIS stock is down 59% this year. Despite its &ldquo;A&rdquo; grade for growth, MicroVision gets an &ldquo;F&rdquo; rating overall in the Portfolio Grader.



<h2>Predictive Oncology (POAI)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/02/artificial-intelligence-ai-brain-tech-1600-768x432-1.jpg"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/artificial-intelligence-ai-brain-tech-1600-768x432-1-300x169.jpg" alt="A concept image representing AI (artificial intelligence)."></a>Predictive Oncology (NASDAQ:<a href="https://investorplace.com/stock-quotes/poai-stock-quote/">POAI</a>) is working to harness the power of artificial intelligence to help bring drugs to market. The company believes that AI can help reduce the time it takes to successfully test and manufacture a drug, and is working specifically on cancer therapies.



The company has a biobank of&nbsp;<a href="https://predictive-oncology.com/biobankai/">150,000 tumor tissue samples</a>&nbsp;and uses machine learning to help it test and discover successful molecules. It also uses AI for drug development and for clinical trials.



And it saw an uptick in revenue in the first quarter, bringing in $419,000 versus $239,000 in the first quarter of 2023.



But the company also posted a loss of $4.2 million and $1.04 per share, versus a loss of $3.4 million and 86 cents per share in the same quarter a year ago.



That&rsquo;s why POAI stock is getting an &ldquo;A&rdquo; rating for growth but an &ldquo;F&rdquo; rating overall in the Portfolio Grader. The stock is down 67% this year.



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/06/7-f-rated-growth-stocks-to-avoid-right-now-june-2024/">7 F-Rated Growth Stocks to Avoid Right Now: June 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 F-Rated Growth Stocks to Avoid Right Now: June 2024

P3 Health Partners GAAP EPS of -$0.15 misses by $0.05, revenue of $379.2M misses by $2.9M

P3 Health Partners Inc. (PIII) Q2 2024 Earnings Call Transcript

BTIG analyst David Larsen maintained a Hold rating on P3 Health Partners (PIII – Research Report) today. The company's shares opened today at $0.60...

BTIG Reaffirms Their Hold Rating on P3 Health Partners (PIII)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Siemens Healthineers AG (SEMHF – Research Report) and P3 Health P...

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF) and P3 Health Partners (PIII)

P3 Health Partners appoints Leif Pedersen as CFO

P3 Health Partners (PIII) has provided an announcement. Leif Pedersen has been appointed as the new Chief Financial Officer of P3 Health Partners I...

P3 Health Partners Announces New CFO and Compensation Details

Lake Street Reaffirms Their Buy Rating on P3 Health Partners (PIII)

P3 Health Partners (PIII) Gets a Buy from Lake Street

Warning: PIII is at high risk of performing badly

HSDT

MVIS

PIIIW

POAI

SBFM

SEMHF

SPCE

Press Releases

P3 Health Partners Announces First Quarter 2024 Results

P3 Health Partners Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

P3 Health Partners Inc. Announces Approximately $42.2 Million Private Placement

P3 Health Partners to Present at Upcoming Investor Conferences

P3 Health Partners Forms Strategic Partnership with Innovaccer to Drive Value-Based Care and Patient Experience

P3 Health Partners Schedules Second Quarter 2024 Earnings Release and Conference Call

P3 Health Partners Announces Second Quarter 2024 Results

P3 Health Partners Names Leif Pedersen New Chief Financial Officer

P3 Health Partners to Present at the LD Micro Main Event XVII

Accolade

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

American Shared Hospital Services Common Stock

American Shared Hospital

ATI Physical Therapy, Inc. Class A Common Stock

ATI Physical Therapy

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

CareMax

DocGo

Enhabit

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group

Nutex Health

Ontrak

Performant Financial Corporation - Common Stock

Performant Finl

Psychemedics

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

Comments

P3 Health Partners

Vendite allo scoperto

P3 Health Partners (NASDAQ:PIII) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO